{"name":"Shanghai SIMR Biotechnology Co., Ltd.","slug":"shanghai-simr-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"active control","genericName":"active control","slug":"active-control","indication":"Various conditions","status":"marketed"}]}],"pipeline":[{"name":"active control","genericName":"active control","slug":"active-control","phase":"marketed","mechanism":"Active control is a type of comparator used in clinical trials to compare the efficacy of a new treatment.","indications":["Various conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9JYTdRRU93dmRJeVY4NEVPN1VnUlJvNFVsa2JyRjk2ZjNyUE9fS3lMTFdubnNRb2VHVEc5TU1lQTJXR2F0Qkthd2tzSHlHMkxETjItLVZnVVA1eklmTlQyUzlqb0c5ZzBvUnBVeV9MenFYcnNPZlRoOEF3?oc=5","date":"2024-11-06","type":"pipeline","source":"fortunebusinessinsights.com","summary":"Neuropathic Pain Market Size, Share | Global Report [2034] - fortunebusinessinsights.com","headline":"Neuropathic Pain Market Size, Share | Global Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPQk13ZkpTeTZpekhFUncybVRuc2hTWVVTUm1SYVdZUkNTQ1JONzBmd2tzclhTUjVETk1leG5BRUxMeHBMbE4xbXd2VmhzWnZ0XzM0SWx2VkJzY1h6MEExYU1nTmdoby1BMndkZ1BMOUxsU3M5SGFqc2RKbE5jNmxhU2hfY3RkTXZFUDc0eTZfaG5Fa1dRVHdkczdUSS1KQWdmZEhqMkk4NklicFVnYXVIMmREdGpUU2NSVTZQUUhBSXBadms0d2tCY29JNEd2VFI2bUdnVjF1THphZ0htemxRTHc3eW52UQ?oc=5","date":"2024-06-10","type":"pipeline","source":"PR Newswire","summary":"Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight - PR Newswire","headline":"Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQllqbTA4WUVyQ0FPSHFtY0ZiR2JMTDhHZUwxdy00UGdJMGcxRXlUZzAwYmN2WU1xUUdxU01QaHZNT1I3MzJCRFVYMDVLdDEzOGJmcFFOMzRKaWtqV1l4NGlBX1hHbi1mNmw4UlZSQzNmbG5oZjVsSjJsUEo2NzExa3ZWV3dMNW85eEI0dkg1ZF9PWk51a0ZhYVRpYlhibmlrN1RKa0Qzdmg4a2Q1U3lNaXZKdGVFbVJVQkwwdkZISVNfYl9BS09icTgxM1ktdTZUS1FJ?oc=5","date":"2020-09-20","type":"pipeline","source":"BioSpace","summary":"Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain - BioSpace","headline":"Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}